ASX:CSLBiotechs
A Look At CSL (ASX:CSL) Valuation As Investors Await Plasma And Vaccine Update In February Results
CSL (ASX:CSL) is back in focus after an ASX filing confirmed 34,261 employee rights have lapsed. This routine equity update leaves investor attention fixed on February’s half-year results and interim dividend announcement.
See our latest analysis for CSL.
CSL’s share price has been choppy, with a 7 day share price return of 2.99% but a 30 day decline of 5.77%, and a 1 year total shareholder return of 36.8% in the red, suggesting momentum has been fading as investors reassess growth and...